Table 2.

Model activity values and differences between treatments among the innate immune system deregulation effector proteins

Gene name	Protein name	SD sign	Canakinumab	Tocilizumab	FDR	ACC
FCGR1A	High affinity immunoglobulin gamma Fc receptor I (CD64)	1	0	− 0.72	7.23E−38	0.995
S100A9	Protein S100-A9	1	− 0.75	0	2.03E−38	0.99
NFKB1	Nuclear factor NF-kappa-B p105 subunit	1	− 1	− 0.56	3.29E−36	0.98
IL8	Interleukin-8 (CXCL8)	1	− 1	− 0.82	9.50E−36	0.97
MYD88	Myeloid differentiation primary response protein MyD88	1	− 0.98	− 0.18	4.09E−33	0.955
RELA	Transcription factor p65 (TF65)	1	− 1	− 0.84	1.95E−33	0.925
ATG5	Autophagy protein 5	1	− 0.91	− 0.37	1.36E−26	0.865
CSF1	Macrophage colony-stimulating factor 1	1	− 0.89	− 0.73	7.23E−07	0.795
SQSTM1	Sequestosome-1	1	− 0.68	− 0.46	1.93E−12	0.795
TLR7	Toll-like receptor 7	-1	− 0.4	− 0.12	1.53E−07	0.745
ICAM1	Intercellular adhesion molecule 1	1	− 0.87	− 1	3.44E−14	0.73
MIF	Macrophage migration inhibitory factor	1	− 0.82	− 0.58	1.33E−04	0.72
S100A12	Protein S100-A12	1	0.16	− 0.13	1.63E−03	0.66
S100A8	Protein S100-A8	1	− 0.23	− 0.22	1.03E−01	0.635
MAP1LC3A	Microtubule-associated proteins 1A/1B light chain 3 (MLP3A)	1	− 0.28	− 0.04	1.80E−04	0.605
INHBA	Inhibin beta A chain	1	0.08	0	4.23E−03	0.57

SD sign column indicates whether the protein is increased/overactivated (1) or reduced/inhibited (− 1) in the context of Still’s disease. The columns canakinumab and tocilizumab present the predicted activity values (ranging from 1, totally activated, to − 1, totally inhibited) for each protein in each MoA model. FDR column indicates the false discovery rate obtained after Mann-Whitney-Wilcoxon test for each protein. The ACC column indicates the cross-validated accuracy of classification of the MoA models for each protein